Breaking News Instant updates and real-time market news.

DPLO

Diplomat Pharmacy

$5.82

0.22 (3.93%)

08:43
12/09/19
12/09
08:43
12/09/19
08:43

Diplomat Pharmacy downgraded to Market Perform from Outperform at Raymond James

Raymond James analyst John Ransom downgraded Diplomat Pharmacy (DPLO) to Market Perform from Outperform after OptumRx, the pharmacy care services business of UnitedHealth Group's (UNH) Optum, agreed to buy the company for $.00 per share in cash.

DPLO Diplomat Pharmacy
$5.82

0.22 (3.93%)

11/13/19
LEHM
11/13/19
DOWNGRADE
Target $3
LEHM
Equal Weight
Diplomat Pharmacy downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Steven Valiquette downgraded Diplomat Pharmacy to Equal Weight from Overweight with a $3 price target.
11/13/19
LEHM
11/13/19
DOWNGRADE
Target $3
LEHM
Equal Weight
Barclays downgrades Diplomat Pharmacy, cuts target to $3 from $7
Barclays analyst Steven Valiquette downgraded Diplomat Pharmacy to Equal Weight from Overweight with a price target of $3, down from $7. Diplomat's strategic review is ongoing, which could lead to a sale of the entire company, or simultaneous asset sales that could unlock value, Valiquette tells investors in a research note. The analyst, however, says the company still face challenges when both competing against and negotiating with larger players in the pharmaceutical services sector. He reduced his projections for another customer loss in the core specialty pharmacy given Diplomat's inability to reach adequate reimbursement terms with a large payor.
11/13/19
11/13/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Skyworks (SWKS) downgraded to Hold from Buy at Canaccord with analyst T. Michael Walkley saying he believes the company is well positioned to grow faster than the broader semi market for the next several years due to smartphone mix among Chinese OEMs requiring integrated Rf solutions, growing IoT opportunities, and the ramping 5G market opportunities. 2. D.R. Horton (DHI) downgraded to Neutral from Buy at Buckingham. 3. Diplomat Pharmacy (DPLO) downgraded to Equal Weight from Overweight at Barclays with analyst Steven Valiquette saying Diplomat's strategic review is ongoing, which could lead to a sale of the entire company, or simultaneous asset sales that could unlock value. 4. Alcoa (AA) downgraded to Underperform from Neutral at BofA/Merrill with analyst Timna Tanners citing limited catalysts and a cautious aluminum view, adding that while the stock price has risen about 16% since reporting Q3, aluminum price was up only about 6% in that time frame. 5. J.M. Smucker (SJM) downgraded to Underperform from Neutral at Credit Suisse with analyst Robert Moskow saying with consensus already below management's FY20 guidance of $8.35-$8.55, it is fair to say that J.M. Smucker is already an out-of-favor stock, but he believes that consensus and the market underestimate the extent to which earnings will need to be revised lower as structural challenges continue to mount. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/15/19
MSCO
11/15/19
NO CHANGE
Target $4
MSCO
Equal Weight
Diplomat Pharmacy 'bull case' value raised to $6 at Morgan Stanley
Morgan Stanley analyst Ricky Goldwasser took a closer look at the potential take out value for Diplomat Pharmacy after the company said it is engaged in advanced discussions and has seen interest in both the whole company and its businesses, leading her to increase her "bull case scenario" value of the stock to $6 from $5. The specialty infusion business "has been the bright light in Diplomat's portfolio" and it could potentially be valued at $4 per share in a take out scenario, estimates Goldwasser. Recent industry conversations raise questions about what price a potential buyer would be willing to pay for the company's core specialty business, which could be worth $2 per share "depending on who the ultimate buyer is," Goldwasser added. She maintains an Equal Weight rating and $4 price target on Diplomat shares.

TODAY'S FREE FLY STORIES

ORGS

Orgenesis

$5.40

0.36 (7.14%)

07:28
01/21/20
01/21
07:28
01/21/20
07:28
Hot Stocks
Orgenesis announces $9.2M private placement »

Orgenesis announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LAC

Lithium Americas

$4.12

-0.05 (-1.20%)

07:27
01/21/20
01/21
07:27
01/21/20
07:27
Hot Stocks
Lithium Americas receives notice of intent for Thacker Pass lithium project »

Lithium Americas…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 12

    Mar

EQT

EQT Corporation

$8.25

-0.28 (-3.28%)

07:27
01/21/20
01/21
07:27
01/21/20
07:27
Upgrade
EQT Corporation rating change  »

EQT Corporation upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VERU

Veru

$4.19

0.07 (1.70%)

07:25
01/21/20
01/21
07:25
01/21/20
07:25
Recommendations
Veru analyst commentary  »

Veru price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NUAN

Nuance

$19.74

-0.02 (-0.10%)

07:24
01/21/20
01/21
07:24
01/21/20
07:24
Hot Stocks
Nuance announces Dragon Medical One availability in France, Belgium, Netherlands »

Nuance Communications…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 05

    Feb

MRSN

Mersana Therapeutics

$8.05

0.42 (5.50%)

07:23
01/21/20
01/21
07:23
01/21/20
07:23
Recommendations
Mersana Therapeutics analyst commentary  »

Mersana Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EOG

EOG Resources

$85.35

-1.66 (-1.91%)

07:22
01/21/20
01/21
07:22
01/21/20
07:22
Upgrade
EOG Resources rating change  »

EOG Resources upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

KMDA

Kamada

$6.62

0.09 (1.38%)

07:21
01/21/20
01/21
07:21
01/21/20
07:21
Hot Stocks
Kamada announces $25M private placement with FIMI Opportunity Fund »

Kamada announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LTHM

Livent

$8.90

0.05 (0.57%)

07:21
01/21/20
01/21
07:21
01/21/20
07:21
Downgrade
Livent rating change  »

Livent downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KVHI

KVH Industries

$10.91

0.05 (0.46%)

, LMT

Lockheed Martin

$425.62

-0.055 (-0.01%)

07:20
01/21/20
01/21
07:20
01/21/20
07:20
Hot Stocks
Lockheed Martin selects KVH fiber optic gyro for infrared search, track system »

KVH Industries (KVHI)…

KVHI

KVH Industries

$10.91

0.05 (0.46%)

LMT

Lockheed Martin

$425.62

-0.055 (-0.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

BIDU

Baidu

$139.64

0.2 (0.14%)

07:18
01/21/20
01/21
07:18
01/21/20
07:18
Recommendations
Baidu analyst commentary  »

Baidu price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

DIS

Disney

$144.25

-0.85 (-0.59%)

07:18
01/21/20
01/21
07:18
01/21/20
07:18
Hot Stocks
Disney+ moves up EMEA launch date to March 24 »

Disney's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Feb

RDHL

RedHill Biopharma

$6.16

0.11 (1.82%)

07:18
01/21/20
01/21
07:18
01/21/20
07:18
Hot Stocks
RedHill Biopharma discontinues promotion of Donnatal, EnteraGam »

RedHill Biopharma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KSU

Kansas City Southern

$166.57

4.77 (2.95%)

07:17
01/21/20
01/21
07:17
01/21/20
07:17
Initiation
Kansas City Southern initiated  »

Benchmark starts Kansas…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BGNE

BeiGene

$170.73

2.85 (1.70%)

07:16
01/21/20
01/21
07:16
01/21/20
07:16
Hot Stocks
BeiGene says Phase 3 trial of tislelizumab meets primary endpoint »

BeiGene announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

CSX

CSX

$76.36

-0.39 (-0.51%)

07:16
01/21/20
01/21
07:16
01/21/20
07:16
Initiation
CSX initiated  »

Benchmark doesn't…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PDD

Pinduoduo

$39.43

-0.07 (-0.18%)

07:15
01/21/20
01/21
07:15
01/21/20
07:15
Recommendations
Pinduoduo analyst commentary  »

Pinduoduo price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MA

MasterCard

$323.60

3.36 (1.05%)

07:15
01/21/20
01/21
07:15
01/21/20
07:15
Initiation
MasterCard initiated  »

MasterCard initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

V

Visa

$204.71

3.765 (1.87%)

07:14
01/21/20
01/21
07:14
01/21/20
07:14
Initiation
Visa initiated  »

Visa initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

  • 30

    Jan

  • 11

    Feb

ETON

Eton Pharmaceuticals

$7.14

-0.3 (-4.03%)

07:14
01/21/20
01/21
07:14
01/21/20
07:14
Hot Stocks
Eton Pharmaceuticals, Xellia announce Biorphen co-promotion agreement »

Eton Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Mar

MYGN

Myriad Genetics

$28.71

-0.21 (-0.73%)

, AZN

AstraZeneca

$51.34

0.84 (1.66%)

07:13
01/21/20
01/21
07:13
01/21/20
07:13
Hot Stocks
Myriad Genetics submits sPMA for BRACAnalysis CDx as companion diagnostic »

Myriad Genetics (MYGN)…

MYGN

Myriad Genetics

$28.71

-0.21 (-0.73%)

AZN

AstraZeneca

$51.34

0.84 (1.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 06

    Feb

  • 13

    Feb

BABA

Alibaba

$227.41

3.53 (1.58%)

07:12
01/21/20
01/21
07:12
01/21/20
07:12
Recommendations
Alibaba analyst commentary  »

Alibaba price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Feb

  • 13

    Feb

SWTX

SpringsWorks Therapeutics

$35.77

0.07 (0.20%)

07:12
01/21/20
01/21
07:12
01/21/20
07:12
Recommendations
SpringsWorks Therapeutics analyst commentary  »

SpringsWorks price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PEGA

Pegasystems

$86.47

0.64 (0.75%)

07:12
01/21/20
01/21
07:12
01/21/20
07:12
Initiation
Pegasystems initiated  »

Pegasystems initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 05

    Mar

  • 10

    Mar

GTHX

G1 Therapeutics

$25.36

-0.42 (-1.63%)

07:11
01/21/20
01/21
07:11
01/21/20
07:11
Recommendations
G1 Therapeutics analyst commentary  »

G1 Therapeutics price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.